上游生物加工设备市场－全球产业规模、份额、趋势、机会和预测，按产品类型、工作流程、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球上游生物加工设备市场价值为 295.4 亿美元，预计到 2030 年将达到 547.6 亿美元，预测期内复合年增长率为 10.67%。

上游生物加工设备市场是指生物製药製造业的一个细分市场，专注于生物产品开发的初始阶段，特别是细胞培养和发酵过程。这包括生物反应器、发酵槽、细胞培养基、过滤系统和混合系统等设备，这些设备对于培养用于生产生物製剂（包括疫苗、单株抗体、荷尔蒙和重组蛋白）的活细胞或微生物至关重要。

受全球对生物製药、个人化医疗和生物相似药需求激增的推动，生物製药市场有望显着成长。随着慢性病和生活方式相关健康问题的日益普遍，对有效生物疗法的需求也日益迫切，这推动了对上游生产能力的投资。此外，一次性生物反应器、自动化和连续生物製程等技术创新正在简化生产流程，提高效率，并降低污染风险，而这些在无菌製药环境中至关重要。

新兴经济体中合约製造组织和生物製药公司的扩张也推动了市场成长，因为它们能够以更低的营运成本获得先进的製造基础设施。此外，政府以资助生物製剂研究和生物製造基础设施建设的形式提供的支持，也进一步刺激了产业扩张。此外，结合不銹钢和一次性组件的混合生物处理系统的日益普及，提供了更大的灵活性和成本效益，对老牌企业和新创公司都具有吸引力。

随着对工艺可扩展性和集约化的日益关注，以及监管部门对产品品质和工艺标准化的重视，预计将推动企业升级其上游加工能力。随着生物製剂产品线的扩展和更复杂分子的开发，上游生物加工设备将在确保高产量和可重复生产方面发挥越来越重要的作用。因此，在技术进步、生物製剂产量成长以及对经济高效且可扩展的生物製造解决方案的需求的推动下，预计上游生物加工设备市场将在已开发地区和发展中地区实现强劲成长。

关键市场驱动因素

生物製药需求不断成长

主要市场挑战

高昂的资本投资和营运成本

主要市场趋势

一次性技术在上游生物加工设备中的集成

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球上游生物加工设备市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依产品类型（生物反应器/发酵槽、细胞培养容器、过滤系统、混合系统、采样系统、其他）
  • 依工作流程（培养基製备、细胞培养、细胞分离）
  • 按最终用户（製药和生物技术公司、合约製造组织、学术和研究机构）
  • 按地区（北美、欧洲、南美、中东和非洲、亚太地区）
• 按公司分类（2024 年）
• 市场地图

第六章：北美上游生物加工设备市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲上游生物加工设备市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太上游生物加工设备市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲上游生物加工设备市场展望

• 市场规模和预测
• 市场占有率和预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲上游生物加工设备市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第十三章：公司简介

• Sartorius AG
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Merck KGaA
• Eppendorf AG
• ZETA GmbH
• PBS Biotech, Inc.
• Thermogenics Inc.
• Pierre Guerin Technologies
• Bioengineering AG

第 14 章：策略建议

第15章调查会社について・免责事项

Global Upstream Bioprocessing Equipment Market was valued at USD 29.54 billion in 2024 and is expected to reach USD 54.76 billion by 2030 with a CAGR of 10.67% during the forecast period.

The Upstream Bioprocessing Equipment Market refers to the segment of the biopharmaceutical manufacturing industry that focuses on the initial phases of biological product development, particularly cell culture and fermentation processes. This includes equipment such as bioreactors, fermenters, cell culture media, filtration systems, and mixing systems that are essential for cultivating living cells or microorganisms used to produce biologics, including vaccines, monoclonal antibodies, hormones, and recombinant proteins.

The market is poised for significant growth driven by the surging global demand for biopharmaceuticals, personalized medicine, and biosimilars. As the prevalence of chronic diseases and lifestyle-related health issues increases, the need for effective biologic therapies is becoming more urgent, propelling investment in upstream manufacturing capacities. Furthermore, technological innovations such as single-use bioreactors, automation, and continuous bioprocessing are streamlining production workflows, enhancing efficiency, and reducing contamination risks, which are vital considerations in sterile pharmaceutical environments.

The expansion of contract manufacturing organizations and biopharmaceutical companies in emerging economies is also fueling market growth by enabling access to advanced manufacturing infrastructure at lower operational costs. In addition, government support in the form of funding for biologics research and biomanufacturing infrastructure development is further stimulating industry expansion. Moreover, increased adoption of hybrid bioprocessing systems that combine stainless steel and disposable components is offering greater flexibility and cost-efficiency, appealing to both established players and startups.

The growing focus on process scalability and intensification, along with regulatory emphasis on product quality and process standardization, is expected to push companies toward upgrading their upstream processing capabilities. As biologic pipelines expand and more complex molecules are developed, upstream bioprocessing equipment will play an increasingly critical role in ensuring high-yield and reproducible production. As a result, the upstream bioprocessing equipment market is anticipated to witness robust growth across developed and developing regions, driven by technological advancements, rising biologics production, and the need for cost-effective and scalable biomanufacturing solutions.

Key Market Drivers

Rising Demand for Biopharmaceuticals

The increasing global demand for biopharmaceuticals, such as monoclonal antibodies, vaccines, and gene therapies, is a primary driver for the Upstream Bioprocessing Equipment Market. The surge in chronic diseases like cancer, diabetes, and autoimmune disorders, coupled with an aging population, has escalated the need for advanced biologics. Upstream bioprocessing equipment, including bioreactors and cell culture systems, is critical for producing these complex therapies at scale.

Governments and healthcare organizations worldwide are prioritizing biopharmaceutical development to address public health challenges, particularly following global health crises like the COVID-19 pandemic, which highlighted the urgency for rapid vaccine production. The shift toward personalized medicine and targeted therapies further amplifies the demand for flexible and scalable bioprocessing solutions. Equipment such as single-use bioreactors enables manufacturers to meet diverse production needs while minimizing contamination risks.

Additionally, emerging markets in Asia-Pacific and Latin America are witnessing increased investments in biopharmaceutical infrastructure, driven by rising healthcare expenditures and growing prevalence of chronic conditions. The ability of upstream equipment to support high-yield cell cultures and recombinant protein production is vital for meeting this demand. As biopharmaceutical companies expand their pipelines to include novel biologics, the Upstream Bioprocessing Equipment Market is poised for sustained growth, fueled by the need for efficient, high-quality production systems that align with stringent regulatory standards and support global health initiatives.

In 2023, global biopharmaceutical production reached 1.2 million liters, with monoclonal antibodies accounting for 45% of output, per the International Federation of Pharmaceutical Manufacturers. Upstream equipment supported 60% of this capacity, with single-use systems contributing to 25% of production. In 2022, vaccine production surged by 30% globally, with bioreactors enabling 2 billion doses, addressing 15% of global demand, particularly in Asia-Pacific, where 200 new facilities were established.

Key Market Challenges

High Capital Investment and Operational Costs

One of the most significant challenges facing the upstream bioprocessing equipment market is the high capital investment required for the installation, commissioning, and validation of biomanufacturing infrastructure. Establishing a biologics manufacturing facility equipped with upstream processing equipment such as bioreactors, centrifuges, media preparation systems, and filtration units involves substantial upfront costs, which can be a barrier for small and mid-sized enterprises. In addition to equipment procurement, expenses related to facility design, utility setup, cleanroom construction, and compliance with regulatory requirements considerably increase the financial burden.

Moreover, the cost of operation is also high due to the need for specialized labor, ongoing maintenance, and frequent calibration of equipment to maintain sterility and productivity. Companies operating in this space must also invest significantly in workforce training and certification to ensure operational proficiency and quality control. While some larger biopharmaceutical companies can absorb these costs due to their expansive budgets and economies of scale, emerging firms and startups often face difficulties in securing adequate funding.

This financial barrier may hinder innovation and delay the time-to-market for critical biologics, especially in regions where public and private investment in biomanufacturing is still limited. The high cost of implementing advanced technologies such as automation, real-time monitoring systems, and single-use components further exacerbates the challenge, particularly for firms seeking cost-efficiency in production.

As the demand for scalable and flexible production systems increases, stakeholders in the upstream bioprocessing equipment market must explore alternative funding models, government grants, and collaborative partnerships to overcome the financial constraints associated with capital investment and operational expenses.

Key Market Trends

Integration of Single-Use Technologies in Upstream Bioprocessing Equipment

The global Upstream Bioprocessing Equipment Market is witnessing a transformative shift with the rapid integration of single-use technologies in bioprocessing workflows. Single-use systems, which include bioreactors, mixers, tubing, and filtration units, are increasingly replacing traditional stainless-steel systems. This trend is particularly driven by the advantages these technologies offer in terms of operational flexibility, reduced contamination risk, and shorter turnaround time between production cycles. In research and development environments, as well as early-phase biologics manufacturing, single-use systems facilitate faster experimentation and scale-up processes without the extensive cleaning and validation requirements of reusable equipment.

Pharmaceutical and biotechnology companies are investing heavily in modular single-use platforms that enable rapid configuration and adjustment based on batch size or biologic type. These platforms allow for high levels of customization, making them suitable for the production of personalized medicines and monoclonal antibodies. Additionally, the reduced capital investment needed for single-use systems appeals to emerging biopharmaceutical firms and contract manufacturing organizations.

Environmental concerns associated with disposability are being addressed through improved material science, with manufacturers developing recyclable or biodegradable single-use components. The growing acceptance of these sustainable options is further accelerating adoption. Regulatory bodies are also becoming more familiar with single-use equipment validation protocols, contributing to their widespread market integration.

As a result, single-use technologies are transforming upstream operations by simplifying workflows, minimizing cross-contamination, and enabling rapid bioprocessing innovation, thereby contributing significantly to the growth of the Upstream Bioprocessing Equipment Market.

Key Market Players

• Sartorius AG
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Merck KGaA
• Eppendorf AG
• ZETA GmbH
• PBS Biotech, Inc.
• Thermogenics Inc.
• Pierre Guerin Technologies
• Bioengineering AG

Report Scope:

In this report, the Global Upstream Bioprocessing Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Upstream Bioprocessing Equipment Market, By Product Type:

• Bioreactors/Fermenters
• Cell Culture Vessels
• Filtration Systems
• Mixing Systems
• Sampling Systems
• Others

Upstream Bioprocessing Equipment Market, By Workflow:

• Media Preparation
• Cell Culture
• Cell Separation

Upstream Bioprocessing Equipment Market, By End-User:

• Pharmaceutical and Biotechnology Companies
• Contract Manufacturing Organizations
• Academic and Research Institutes

Upstream Bioprocessing Equipment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
• South America
  • Brazil
  • Argentina
  • Colombia
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Upstream Bioprocessing Equipment Market.

Available Customizations:

Global Upstream Bioprocessing Equipment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Upstream Bioprocessing Equipment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Bioreactors/Fermenters, Cell Culture Vessels, Filtration Systems, Mixing Systems, Sampling Systems, Others)
  • 5.2.2. By Workflow (Media Preparation, Cell Culture, Cell Separation)
  • 5.2.3. By End-User (Pharmaceutical and Biotechnology Companies, Contract Manufacturing Organizations, Academic and Research Institutes)
  • 5.2.4. By Region (North America, Europe, South America, Middle East & Africa, Asia Pacific)
• 5.3. By Company (2024)
• 5.4. Market Map

6. North America Upstream Bioprocessing Equipment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Workflow
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Upstream Bioprocessing Equipment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Workflow
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Upstream Bioprocessing Equipment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Workflow
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Upstream Bioprocessing Equipment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Workflow
      • 6.3.3.2.3. By End-User

7. Europe Upstream Bioprocessing Equipment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Workflow
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Upstream Bioprocessing Equipment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Workflow
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Upstream Bioprocessing Equipment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Workflow
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Upstream Bioprocessing Equipment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Workflow
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Upstream Bioprocessing Equipment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Workflow
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Upstream Bioprocessing Equipment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Workflow
      • 7.3.5.2.3. By End-User

8. Asia Pacific Upstream Bioprocessing Equipment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Workflow
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Upstream Bioprocessing Equipment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Workflow
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Upstream Bioprocessing Equipment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Workflow
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Upstream Bioprocessing Equipment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Workflow
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Upstream Bioprocessing Equipment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Workflow
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Upstream Bioprocessing Equipment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Workflow
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Upstream Bioprocessing Equipment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Workflow
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Upstream Bioprocessing Equipment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Workflow
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Upstream Bioprocessing Equipment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Workflow
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Upstream Bioprocessing Equipment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Workflow
      • 9.3.3.2.3. By End-User

10. South America Upstream Bioprocessing Equipment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Workflow
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Upstream Bioprocessing Equipment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Workflow
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Upstream Bioprocessing Equipment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Workflow
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Upstream Bioprocessing Equipment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Workflow
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends and Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Company Profiles

• 13.1. Sartorius AG
  • 13.1.1. Business Overview
  • 13.1.2. Key Revenue and Financials
  • 13.1.3. Recent Developments
  • 13.1.4. Key Personnel
  • 13.1.5. Key Product/Services Offered
• 13.2. Thermo Fisher Scientific Inc.
• 13.3. Danaher Corporation
• 13.4. Merck KGaA
• 13.5. Eppendorf AG
• 13.6. ZETA GmbH
• 13.7. PBS Biotech, Inc.
• 13.8. Thermogenics Inc.
• 13.9. Pierre Guerin Technologies
• 13.10. Bioengineering AG

14. Strategic Recommendations

15. About Us & Disclaimer